Abstract
The tissue-selective inhibition of cholesterol synthesis by pravastatin was evaluated pharmacokinetically and pharmacodynamically. Plasma, tissue, urine, and bile concentrations were measured after iv bolus injection of pravastatin to rats at various doses. The total body clearance and steady state volume of distribution decreased with increasing dose. A saturable biliary excretion was also observed. The time course of plasma and liver concentrations was described by a three-compartment model, consisting of a central compartment, a deep compartment with an nonsaturable uptake process, and a shallow compartment with saturable uptake and nonsaturable elimination processes. It suggests that a mechanism for the decrease in the total body clearance and distribution volume might be explained by a saturation of pravastatin uptake into the liver. Plasma concentration data after oral administration was also fitted to the same model by connecting an absorption compartment to the shallow compartment. The inhibitory activity of pravastatin against cholesterol synthesis in liver could be related to the concentration in the shallow compartment via a sigmoidal Emax model and the obtained pharmacodynamic parameters were comparable to those in vitro. Results suggest that the carrier-mediated hepatic uptake of pravastatin is actually responsible for the hepatoselective inhibition of cholesterol synthesis under physiological conditions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
J. M. Hoeg and H. B. Brewer, Jr. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. J. Am. Med. Assoc. 258:3532–3536 (1987).
D. R. Illingworth and J. A. Tobert. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin. Ther. 16:366–385 (1994).
A. T. M. Serajuddin, S. A. Ranadive, and E. M. Mahoney. Relative lipophilicities, solubilities, and structure-pharmacological consideration of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80:830–834 (1991).
T. Komai, E. Shigehara, T. Tokui, T. Koga, M. Ishigami, C. Kuroiwa, and S. Horiuchi. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem. Pharmacol. 43:667–670 (1992).
K. Ziegler and S. Hummelsiep. Hepatoselective carrier-mediated sodium-independent uptake of pravastatin and pravastatin-lactone. Biochim. Biophys. Acta 1153:23–33 (1993).
M. Yamazaki, H. Suzuki, M. Hanano, T. Tokui, T. Komai, and Y. Sugiyama. Na+-independent multispecific anion transporter mediates active transport of pravastatin into at liver. Am. J. Physiol. 264:G36–G44 (1993).
Y. Tsujita, M. Kuroda, Y. Shimada, K. Tanizawa, M. Arai, I. Kaneko, M. Tanaka, H. Masuda, C. Tarumi, Y. Watanabe, and S. Fuji. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: Tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta 877:50–60 (1986).
T. Koga, Y. Shimada, M. Kuroda, Y. Tsujita, K. Hasegawa, and M. Yamazaki. Tissue-selective inhibition of cholesterol synthesis in vitro by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim. Biophys. Acta 1045:115–120 (1990).
T. Koga, K. Fukuda, Y. Shimada, M. Fukami, H. Koike, and Y. Tsujita. Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. Eur. J. Biochem. 209:315–319 (1992).
A. K. van Vliet, G. C. F. van Thiel, R. H. Huisman, H. Moshage, S. H. Yap, and L. H. Cohen. Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim. Biophys. Acta 1254:105–111 (1995).
P. K. Gupta and C. T. Hung. Quantitative evaluation of targeted drug delivery systems. Int. J. Pharm. 56:217–226 (1989).
G. Levy. Targeted drug delivery: Some pharmacokinetic considerations. Pharm. Res. 4:3–4 (1987).
A. Boddy and L. Aarons. Pharmacokinetic and pharmacodynamic aspects of site-specific drug delivery. Adv. Drug Deliv. Rev. 3:155–163 (1989).
J. I. Germershausen, V. M. Hunt, R. G. Bostedor, P. J. Bailey, J. D. Karkas, and A. W. Alberts. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochim. Biophys. Res. Commun. 158:667–675 (1989).
M. Berman, E. Shahn, and M. F. Weiss. The routine fitting of kinetic data to models: A mathematical formalism for digital computers. Biophys. J. 2:275–287 (1962).
A. Endo, M. Kuroda, and Y. Tsujita. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrium. J. Antibiot. 29:1346–1348 (1977).
A. Endo, Y. Tsujita, M. Kuroda, and K. Tanzawa. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 77:31–36 (1977).
T. M. A. Bocan, E. Ferguson, W. McNally, P. D. Uhlendorf, S. B. Muller, P. Dehart, D. R. Sliskovic, B. D. Roth, B. R. Krause, and R. S. Newton. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1123:133–144 (1992).
T. Komai, K. Kawai, T. Tokui, Y. Tokui, C. Kuroiwa, E. Shigehara, and M. Tanaka. Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys. Eur. J. Drug Metab. Pharmacokin. 17:103–113 (1992).
S. M. Singhvi, H. Y. Pan, R. A. Morrison, and D. A. Willard. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 29:239–243 (1990).
D. W. Everett, T. J. Chando, G. C. Didonato, S. M. Singhvi, H. Y. Pan, and S. H. Weinstein. Biotransformation of pravastatin sodium in human. Drug Metab. Dispos. 19:740–748 (1991).
J. H. Lin, Y. Sugiyama, S. Awazu, and M. Hanano. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J. Pharmacokin. Biopharm. 10:649–661 (1982).
A. Tsuji, H. Takanaga, I. Tamai, and T. Terasaki, Transcellular transport of benzoic acid across Caco-2 cells by a pH-dependent and carrier-mediated transport mechanism. Pharm. Res. 11:30–37 (1994).
K. Sasahara. Pharmacokinetics of HMG-CoA reductase inhibitors. Prog. Med. 11:2413–2427 (1991).
G. A. Keller, M. C. Barton, D. J. Shapiro, and S. J. Singer. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase is present in peroxisome in normal rat liver cells. Proc. Natl. Acad. Sci. U.S. 82:770–774 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hatanaka, T., Honda, S., Sasaki, S. et al. Pharmacokinetic and Pharmacodynamic Evaluation for Tissue-Selective Inhibition of Cholesterol Synthesis by Pravastatin. J Pharmacokinet Pharmacodyn 26, 329–347 (1998). https://doi.org/10.1023/A:1023237510458
Published:
Issue Date:
DOI: https://doi.org/10.1023/A:1023237510458